$SRNE News: "SRNE (5.12 -21.23%): Continued volatility; pulls back after spiking by as much as circa +282% during the previous two sessions following its update for its anti-SARS-CoV-2 antibody, STI-1499. The stock has now moderated its three-session performance to a net gain of circa +95% GOSS (12.45 -17.08%): Announced concurrent public offerings of 9,433,963 shares of common stock, priced at $13.25/share, and $200.0 mln aggregate principal amount of 5.00% convertible senior notes due 2027; gross proceeds are expected to be approx. $325.0 mln, and these will be used to fund research and development for co's product candidates, among other intended purposes.
  • 1
1 Like